NCT00555204

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 337 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	ABT-089	10 mg - capsules once daily for 12 weeks
DRUG	ABT-089	5 mg - capsules once daily for 12 weeks
DRUG	ABT-089	15 mg - capsules once daily for 12 weeks
DRUG	ABT-089	20 mg - capsules once daily for 12 weeks
DRUG	ABT-089	30 mg - capsules once daily for 12 weeks
DRUG	ABT-089	35 mg - capsules once daily for 12 weeks
DRUG	placebo	placebo - capsules once daily for 12 weeks

Timeline

• Start date: 2007-11-01
• Primary completion: 2009-06-01
• First posted: 2007-11-08
• Last updated: 2011-08-23

Locations

42 sites across 1 country: United States